New Two-Target cancer drug enters first human trials
NCT ID NCT06126666
Summary
This is the first human study of an experimental drug called ABL103 for people with advanced solid tumors that have progressed despite standard treatments. The study aims to find the safest dose and see if the drug shows early signs of fighting cancer. It will enroll 96 adults whose cancer has spread or cannot be surgically removed and who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, Seoul, 13620, South Korea
Contact
Contact Email: •••••@•••••
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, Seoul, 03080, South Korea
Contact Email: •••••@•••••
-
Sevrance Hospital
RECRUITINGSeoul, South Korea, 03722, South Korea
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.